Coherus BioSciences (CHRS) Priced

Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.

Health Care - Biotechnology

IPO Performance
Latest Trade $22.70 0.00 (0.0%)
First Day Return -6.6%
Return from IPO 68.1%
 
Coherus BioSciences IPO News more
  • .
IPO Data
IPO File Date 09/25/2014
Offer Price $13.50
Price Range $12.00 - $15.00
Offer Shares (mm) 6.3
Deal Size ($mm) 85
 
IPO Data
IPO Date 11/06/2014
Offer Price $13.50
Price Range $12.00 - $15.00
Offer Shares (mm) 6.3
Deal Size ($mm) $85
 
Underwriters
more
Business Overview
Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.
Developing a biosimilar of Amgen's Enbrel treatment for inflammatory diseases.
more
Company Data
Headquarters Redwood City, CA
Founded 2010
Employees 46
Website www.coherus.com
 

Performance vs. IPO Index (IPOUSA)